Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Trouw

Showing results (251-260 of 283) with videos related to

Pageof 29
Sort By:
RMD Open|March 1, 2016
Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED studyGülşah Akdemir, Marije K Verheul, Lotte Heimans, et al.
Clinical and Experimental Rheumatology|September 8, 2020
Mass-spectrometric identification of carbamylated proteins present in the joints of rheumatoid arthritis patients and controlsMarije K Verheul, George M C Janssen, Arnoud de Ru, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 12, 2011
Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damageJing Shi, Rachel Knevel, Parawee Suwannalai, et al.
Annals of the Rheumatic Diseases|May 1, 2016
Anti-carbamylated protein antibodies: a specific hallmark for rheumatoid arthritis. Comparison to conditions known for enhanced carbamylation; renal failure, smoking and chronic inflammationM K Verheul, S J H van Erp, D van der Woude, et al.
Frontiers in Immunology|May 31, 2024
Targeted complement inhibition using bispecific antibodies that bind local antigens and endogenous complement regulatorsHaiyu Wang, Fleur S van de Bovenkamp, Douwe J Dijkstra, et al.
Frontiers in Immunology|April 5, 2017
Type I Interferon Gene Response Is Increased in Early and Established Rheumatoid Arthritis and Correlates with Autoantibody ProductionJulio E Castañeda-Delgado, Yadira Bastián-Hernandez, Noe Macias-Segura, et al.
PNAS Nexus|July 30, 2025
Modulation of immunoglobulin G oligomerization by variable domain glycans: A mechanism to regulate complement activationRoxane Biersteker, Leoni Abendstein, Sanne van de Bovenkamp, et al.
Journal of Autoimmunity|June 24, 2025
Post-translationally modified proteins bind and activate complement with implications for cellular uptake and autoantibody formationM D van den Beukel, L Zhang, S van der Meulen, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 4, 2023
Human anti-C1q autoantibodies bind specifically to solid-phase C1q and enhance phagocytosis but not complement activationDouwe J Dijkstra, Fleur S van de Bovenkamp, Leoni Abendstein, et al.
Annals of the Rheumatic Diseases|June 2, 2019
Different classes of anti-modified protein antibodies are induced on exposure to antigens expressing only one type of modificationArieke Suzanna Berendina Kampstra, Jacqueline Stephanie Dekkers, Mikhail Volkov, et al.
Pageof 29

Showing results (251-260 of 283) with videos related to

Sort By:
Pageof 29
RMD Open|March 1, 2016
Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED studyGülşah Akdemir, Marije K Verheul, Lotte Heimans, et al.
Clinical and Experimental Rheumatology|September 8, 2020
Mass-spectrometric identification of carbamylated proteins present in the joints of rheumatoid arthritis patients and controlsMarije K Verheul, George M C Janssen, Arnoud de Ru, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 12, 2011
Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damageJing Shi, Rachel Knevel, Parawee Suwannalai, et al.
Annals of the Rheumatic Diseases|May 1, 2016
Anti-carbamylated protein antibodies: a specific hallmark for rheumatoid arthritis. Comparison to conditions known for enhanced carbamylation; renal failure, smoking and chronic inflammationM K Verheul, S J H van Erp, D van der Woude, et al.
Frontiers in Immunology|May 31, 2024
Targeted complement inhibition using bispecific antibodies that bind local antigens and endogenous complement regulatorsHaiyu Wang, Fleur S van de Bovenkamp, Douwe J Dijkstra, et al.
Frontiers in Immunology|April 5, 2017
Type I Interferon Gene Response Is Increased in Early and Established Rheumatoid Arthritis and Correlates with Autoantibody ProductionJulio E Castañeda-Delgado, Yadira Bastián-Hernandez, Noe Macias-Segura, et al.
PNAS Nexus|July 30, 2025
Modulation of immunoglobulin G oligomerization by variable domain glycans: A mechanism to regulate complement activationRoxane Biersteker, Leoni Abendstein, Sanne van de Bovenkamp, et al.
Journal of Autoimmunity|June 24, 2025
Post-translationally modified proteins bind and activate complement with implications for cellular uptake and autoantibody formationM D van den Beukel, L Zhang, S van der Meulen, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 4, 2023
Human anti-C1q autoantibodies bind specifically to solid-phase C1q and enhance phagocytosis but not complement activationDouwe J Dijkstra, Fleur S van de Bovenkamp, Leoni Abendstein, et al.
Annals of the Rheumatic Diseases|June 2, 2019
Different classes of anti-modified protein antibodies are induced on exposure to antigens expressing only one type of modificationArieke Suzanna Berendina Kampstra, Jacqueline Stephanie Dekkers, Mikhail Volkov, et al.
Pageof 29